Nasdaq-listed Amgen has agreed to acquire Oxford-based Dark Blue Therapeutics in a deal valued at around £622 million. The swoop is set to strengthen the US MedTech giant’s early-stage oncology pipeline and its focus on targeted protein degradation. Private firm Dark Blue Therapeutics is currently developing first-in-class small molecule therapies designed to degrade disease-driving proteins.  … Continue reading Nasdaq’s Amgen swoops for Dark Blue Therapeutics in £622m deal